Sagun Parakh

2.4k total citations · 1 hit paper
79 papers, 1.5k citations indexed

About

Sagun Parakh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Sagun Parakh has authored 79 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 20 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Sagun Parakh's work include Cancer Immunotherapy and Biomarkers (22 papers), CAR-T cell therapy research (18 papers) and HER2/EGFR in Cancer Research (13 papers). Sagun Parakh is often cited by papers focused on Cancer Immunotherapy and Biomarkers (22 papers), CAR-T cell therapy research (18 papers) and HER2/EGFR in Cancer Research (13 papers). Sagun Parakh collaborates with scholars based in Australia, United States and United Kingdom. Sagun Parakh's co-authors include Hui Gan, Andrew M. Scott, Umbreen Hafeez, Adam Parslow, Jonathan Cebon, Miles C. Andrews, Oliver Klein, Ravi Devraj, Suneel Apte and B. Ramesh Rao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Sagun Parakh

73 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antibody–Drug Conjugates for Cancer Therapy

2020 278 citations Umbreen Hafeez, Sagun Parakh et al. profile →

Peers

Countries citing papers authored by Sagun Parakh

Since Specialization

Citations

This map shows the geographic impact of Sagun Parakh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sagun Parakh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sagun Parakh more than expected).

Fields of papers citing papers by Sagun Parakh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sagun Parakh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sagun Parakh. The network helps show where Sagun Parakh may publish in the future.

Co-authorship network of co-authors of Sagun Parakh

This figure shows the co-authorship network connecting the top 25 collaborators of Sagun Parakh. A scholar is included among the top collaborators of Sagun Parakh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sagun Parakh. Sagun Parakh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer 2025 ·Lung Cancer ·(unknown), Martin Faltys, Marliese Alexander, (unknown), Sagun Parakh, (unknown), Lydia Warburton, A Fantoni, Timothy Clay, Surein Arulananda, (unknown), Steven Kao, Ivan Da Silva, Lauren Brown, Brett Hughes, (unknown), Benjamin Solomon, Thomas John	0
2	Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 2025 ·Molecular Cancer Therapeutics ·Sagun Parakh, (unknown), Deliang Cao, Angela Rigopoulos, (unknown), Ingrid J.G. Burvenich, Carmel Murone, Christian Wichmann, (unknown), (unknown), Adam Parslow, (unknown), Laura D. Osellame, Peter W. Janes, Fiona E. Scott, Zhanqi Liu, Hui Gan, Andrew M. Scott	1
3	Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 2025 ·Sagun Parakh, (unknown), Deliang Cao, Angela Rigopoulos, (unknown), Ingrid J.G. Burvenich, Carmel Murone, Christian Wichmann, (unknown), (unknown), Adam Parslow, (unknown), Laura D. Osellame, Peter W. Janes, Fiona E. Scott, Zhanqi Liu, Hui Gan, Andrew M. Scott	1
4	Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial 2025 ·Clinical Cancer Research ·Akhila Balasubramanian, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jodie Palmer, Michael Christie, Ashray Gunjur, Surein Arulananda, Sagun Parakh, David J. Adams, Belinda Phipson, Sean M. Grimmond, Jonathan Cebon, Marie-Liesse Asselin-Labat, Thomas John	0
5	OA05.04 A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced/Metastatic NSCLC: ZEAL-1L 2025 ·Journal of Thoracic Oncology ·Suresh S. Ramalingam, (unknown), (unknown), (unknown), Michael B. Thomas, Rachel E. Sanborn, Julien Mazières, David R. Spigel, (unknown), Johan Isaksson, (unknown), (unknown), Elena Poddubskaya, Yoon Jun Kim, Sagun Parakh, Wei Liu, (unknown), (unknown), George Chiu, (unknown)	1
6	Utility of bronchoalveolar lavage in checkpoint inhibitor pneumonitis evaluation: a narrative review 2025 ·Translational Lung Cancer Research ·(unknown), Sagun Parakh, (unknown), Farzaneh Atashrazm, Vivek Naranbhai, Nicole Goh, (unknown), Tracy L. Leong	0
7	Implementation of a nurse-led, multidisciplinary model of care for older adults with cancer: a process evaluation protocol 2024 ·BMJ Open ·(unknown), (unknown), (unknown), Kathryn Lee, (unknown), Jeremy Rodrigues, Paul Yates, Surein Arulananda, Sagun Parakh	2
8	Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Jermaine Coward, Ganessan Kichenadasse, John Park, Sagun Parakh, Gary Richardson, Mark Voskoboynik, John D. Powderly, (unknown), Shutong Liu, Yaling Huang, Shu‐Hui Liu, (unknown)	0
9	Lurbinectedin in small cell lung cancer: real‐world experience of a multicentre national early access programme 2024 ·Australasian Journal of Paramedicine ·Marliese Alexander, (unknown), Sagun Parakh, Paul Mitchell, Timothy Clay, Steven Kao, Brett Hughes, Malinda Itchins, Benjamin Y. Kong, Nick Pavlakis, Benjamin Solomon, Thomas John	5
10	Antibody-drug conjugates: beyond current approvals and potential future strategies 2022 ·SHILAP Revista de lepidopterología ·(unknown), Sagun Parakh, Andrew M. Scott, Hui Gan	14
11	ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with ⁸⁹ Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol 2022 ·BMJ Open ·Fiona Hegi‐Johnson, Stacey E. Rudd, Christian Wichmann, Tim Akhurst, Peter Roselt, (unknown), Thomas John, Lisa Devereux, Paul S. Donnelly, Rodney J. Hicks, Andrew M. Scott, Daniel Steinfort, Stephen B. Fox, Benjamin J. Blyth, Sagun Parakh, Gerard G. Hanna, Jason Callahan, Kate Burbury, Michael MacManus	15
12	Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease 2021 ·JCO Precision Oncology ·(unknown), (unknown), Sagun Parakh, Steven Kao, Craig Lewis, Melvin Chin, Mark Voskoboynik, Malinda Itchins, Ross Jennens, A. Broad, (unknown), Benjamin Solomon	4
13	PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma 2021 ·Frontiers in Immunology ·Sagun Parakh, Ashan Musafer, (unknown), (unknown), Connie S.N. Li Wai Suen, Candani Tutuka, Matteo S. Carlino, Alexander M. Menzies, Richard A. Scolyer, Jonathan Cebon, Alexander Dobrovic, Georgina V. Long, Oliver Klein, Andreas Behren	12
14	Young adults diagnosed with high grade gliomas: Patterns of care, outcomes, and impact on employment 2019 ·Journal of Clinical Neuroscience ·Umbreen Hafeez, (unknown), (unknown), Caroline Lum, (unknown), (unknown), Lawrence Cher, Anna K. Nowak, Hui Gan, Sagun Parakh	1
15	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma 2018 ·Frontiers in Immunology ·Jessica Da Gama Duarte, Sagun Parakh, Miles C. Andrews, Katherine Woods, Anupama Pasam, Candani Tutuka, Simone Ostrouska, Jonathan M. Blackburn, Andreas Behren, Jonathan Cebon	47
16	Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a tertiary centre 2017 ·Critical Care and Resuscitation ·F. Ha, Andrew Weickhardt, Sagun Parakh, Andrew Vincent, Neil J. Glassford, Stephen Warrillow, Daryl Jones	10
17	Evolution of anti-HER2 therapies for cancer treatment 2017 ·Cancer Treatment Reviews ·Sagun Parakh, Hui Gan, Adam Parslow, Ingrid J.G. Burvenich, Antony W. Burgess, Andrew M. Scott	69
18	Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a general tertiary centre 2016 ·Annals of Oncology ·(unknown), Andrew Weickhardt, Sagun Parakh, Neil J. Glassford, Stephen Warrillow, Daryl Jones	2
19	Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia 2015 ·Journal of Geriatric Oncology ·Sagun Parakh, Hui‐Li Wong, Rajat Rai, Sayed Ali, Kathryn Field, Jeremy Shapiro, Rachel Wong, Louise Nott, Peter Gibbs, Desmond Yip	20
20	Development of a Melting Tablet Containing Promethazine HCl Against Motion Sickness 2008 ·AAPS PharmSciTech ·Rahul V. Haware, P. Chaudhari, Sagun Parakh, Annette Bauer‐Brandl	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact